Scholar Rock
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Scholar Rock 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRRK
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
CEODavid L. Hallal
CEODavid L. Hallal
Employees196
Employees196
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2012
Founded2012
Employees196
Employees196
SRRK Key Statistics
Market cap3.11B
Market cap3.11B
Price-Earnings ratio-10.57
Price-Earnings ratio-10.57
Dividend yield—
Dividend yield—
Average volume3.55M
Average volume3.55M
High today$33.68
High today$33.68
Low today$31.62
Low today$31.62
Open price$31.65
Open price$31.65
Volume2.53M
Volume2.53M
52 Week high$46.98
52 Week high$46.98
52 Week low$22.71
52 Week low$22.71
SRRK News
TipRanks 1d
Scholar Rock Faces Regulatory Concerns at Catalent FacilityElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
The Motley Fool 2d
Why Scholar Rock Stock Got Socked on MondayThe biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects. A potential delay in an important submis...
TipRanks 6d
Scholar Rock initiated with a Buy at BofA on SMA therapy potentialAs previously reported, BofA analyst Tazeen Ahmad initiated coverage of Scholar Rock (SRRK) with a Buy rating and $53 price target Scholar Rock is developing an...
Analyst ratings
100%
of 13 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own SRRK. This list is generated using Robinhood data, and it’s not a recommendation.